Citations

Clear

246 citation(s) found for "Study, Alfa".

Implementation and Validation of Face De‐Identification (de‐facing) in ADNI‐4
Schwarz, Christopher G., Choe, Mark, Rossi, Stéphanie, Ittyerah, Ranjit, Fletcher, Evan, Singh, Baljeet , Malone, Ian B., Prosser, Lloyd , Matoush, Leonard, Ward, Chadwick P., Prakaashana, Carl M., DeCarli, Charles , Weiner, Michael S. W., Malone, Ian B. , Schwarz, Christopher G. , Tosun, Duygu , Yushkevich, Paul A. , Rossi, Stephanie, Das, Sandhitsu R. , Maillard, Pauline , Harvey, Danielle , Senjem, Matthew L. , Barkhof, Frederik , Jack, Clifford R.

Mayo Clinic

Alzheimer's & Dementia | January 9, 2025 | Volume: 20 | Issue: S9 | Pages: No page available

10.1002/alz.093642 Get It

AbstractBackgroundRecent advances in automatic face recognition have increased the risk that de‐identified research imaging data could be re‐identified from face imagery in brain scans.MethodAn ADNI committee of independent imaging experts evaluated 11 published techniques for face‐deidentification (“de‐facing”) and selected four algorithms (FSL‐UK Biobank, HCP/XNAT, mri_reface, and BIC) for formal testing using 183 longitudinal scans of 61 racially and ethnically diverse ADNI participants, evaluated by their facial feature removal on 3D rendered surfaces (confirming sufficient privacy protection) and by comparing measurements from ADNI routine image analyses on unmodified vs. de‐faced images (confirming negligible side effects on analyses).ResultEffects of the de‐facing methods on FreeSurfer at UCSF (Figure 1‐top), ASHS at University of Pennsylvania (Figure 1 bottom‐left), and longitudinal atrophy at Mayo Clinic (Figure 1 bottom‐right) were comparable with each other and sufficiently small vs. unmodified scans to recommend de‐facing in ADNI‐4. The FSL and mri_reface methods were more thorough in removing facial features, partly because these also removed ears (Figure 2‐top). mri_reface was recommended for ADNI‐4 primarily because fewer (zero) images had modified brain (Figure 2‐bottom), and ADNI leadership approved de‐facing with mri_reface. ADNI performed a second validation of its latest version on another diverse sample of 100 ADNI‐3 participants. These analyses included: boundary shift interval at University College London, where average differences in measurements were all <0.05%; cortical white matter hyperintensities at UC Davis, where they found “minimum impact” (R>0.97); and others.ConclusionADNI‐4 de‐faces all indicated image types (Table 1) before subsequent pre‐processing, analyses, and public release. Sites upload images to the central repository (LONI), where they are queued to the MRI Core at Mayo Clinic for de‐facing. Image types requiring de‐facing are de‐faced using mri_reface. Trained analysts inspect de‐faced images to confirm complete removal of the face and complete non‐modification of the brain, and any flagged images are re‐processed manually until issues are resolved. De‐faced images are converted back to DICOM and re‐uploaded for further distribution. Image types not requiring de‐facing are indicated to proceed directly to subsequent steps. In summary, ADNI‐4 has adopted mri_reface because it successfully de‐faces without substantially affecting brain measurements.
Overview of Alzheimer's Disease Neuroimaging Initiative and future clinical trials
Weiner, Michael W. , Kanoria, Shaveta , Miller, Melanie J. , Aisen, Paul , Conti, Catherine , Diaz, Adam , Flenniken, Derek , Harvey, Danielle , Jack, Clifford R. , Jagust, William J. , Morris, John C. , Nosheny, Rachel L. , Okonkwo, Ozioma C. , Perrin, Richard J. , Petersen, Ronald C. , Saykin, Andrew J. , Shaw, Leslie M. , Tosun, Duygu , Initiative, for the Alzheimer's Disease Neuroimaging, Jack, Clifford R , Saykin, Andrew J , Morris, John C , Harvey, Danielle J , Tosun, Duygu , Weiner, Michael W , Beckett, Laurel , Green, Robert C. , Lee, Edward B. , Nho, Kwangsik T. , Mindt, Mónica Rivera , Toga, Arthur W. , Veitch, Dallas P. , Initiative, for the Alzheimer's Disease Neuroimaging

Mayo Clinic

Alzheimer's & Dementia | December 23, 2024 | Volume: 21 | Issue: 1 | Pages: No page available

10.1002/alz.14321 | PMID 39711072 Get It

Abstract The overall goal of the Alzheimer's Disease Neuroimaging Initiative (ADNI) is to optimize and validate biomarkers for clinical trials while sharing all data and biofluid samples with the global scientific community. ADNI has been instrumental in standardizing and validating amyloid beta (Aβ) and tau positron emission tomography (PET) imaging. ADNI data were used for the US Food and Drug Administration (FDA) approval of the Fujirebio and Roche Elecsys cerebrospinal fluid diagnostic tests. Additionally, ADNI provided data for the trials of the FDA‐approved treatments aducanumab, lecanemab, and donanemab. More than 6000 scientific papers have been published using ADNI data, reflecting ADNI's promotion of open science and data sharing. Despite its enormous success, ADNI has some limitations, particularly in generalizing its data and findings to the entire US/Canadian population. This introduction provides a historical overview of ADNI and highlights its significant accomplishments and future vision to pioneer “the clinical trial of the future” focusing on demographic inclusivity. Highlights The Alzheimer's Disease Neuroimaging Initiative (ADNI) introduced a novel model for public‐private partnerships and data sharing. It successfully validated amyloid and Tau PET imaging, as well as CSF and plasma biomarkers, for diagnosing Alzheimer's disease. ADNI generated and disseminated vital data for designing AD clinical trials.
The POINTER Imaging baseline cohort: Associations between multimodal neuroimaging biomarkers, cardiovascular health, and cognition
Harrison, Theresa M. , Ward, Tyler J. , Taggett, Jacinda , Maillard, Pauline , Jung, Youngkyoo , Lovato, Laura, Jagust, William J., Harvey, Danielle , Masdeu, Joseph C. , Oh, Hwamee , Aggarwal, Neelum T. , Cleveland, Maryjo, Whitmer, Rachel A. , Farias, Sarah Tomaszewski , Salloway, Stephen , Pavlik, Valory , Yu, Melissa , Snyder, Heather M. , Carrillo, María C. , Baker, Laura D. , DeCarli, Charles , Landau, Susan, Group, for the U.S. POINTER Study, DeCarli, Charles , Harvey, Danielle J , Maillard, Pauline , Harrison, Theresa M , Lockhart, Samuel N. , Koeppe, Robert A. , Masdeu, Joseph C , Gitelman, Darren R. , Espeland, Mark Andrew , Tangney, Christy , Vemuri, Prashanthi , Group, for the U.S. POINTER Study

Mayo Clinic

Alzheimer's & Dementia | December 6, 2024 | Volume: 21 | Issue: 1 | Pages: No page available

10.1002/alz.14399 | PMID 39641363 Get It

Abstract INTRODUCTION The U.S. Study to Protect Brain Health Through Lifestyle Intervention to Reduce Risk (U.S. POINTER) is evaluating lifestyle interventions in older adults at risk for cognitive decline and dementia. Here we characterize the baseline data set of the POINTER Imaging ancillary study. METHODS Participants underwent health and cognitive assessments and neuroimaging with multimodal positron emission tomography (PET) (beta‐amyloid [Aβ] and tau) and magnetic resonance imaging (MRI). Framingham risk score (FRS) was used to quantify cardiovascular disease (CVD) risk. RESULTS A total of 1052 participants (31% from underrepresented ethnoracial groups) were enrolled. Compared to Aβ−, Aβ+ (29%) participants were older, had higher apolipoprotein E ( APOE ) ε4 carriage rate and white matter hyperintensity volume, and greater temporal tau. FRS was related to MRI measures, but not AD biomarkers. FRS and tau had independent effects on cognition. DISCUSSION In this heterogenous, at‐risk cohort, CVD risk was related to more abnormal brain structure and poorer cognition, representing a putative non‐AD (Alzheimer's disease) pathway to brain injury and cognitive decline. Highlights The U.S. Study to Protect Brain Health Through Lifestyle Intervention to Reduce Risk (U.S. POINTER) cohort is enriched for cardiovascular disease (CVD) and poor lifestyle POINTER Imaging collected multimodal neuroimaging data in this unique, at‐risk cohort Amyloid burden was related to age, apolipoprotein E ( APOE ) ε4 carriage, and measures of disease progression Associations between amyloid and tau, and tau and cognition, were relatively weak CVD risk and tau pathology were independently related to memory
Positron emission tomography harmonization in the Alzheimer's Disease Neuroimaging Initiative: A scalable and rigorous approach to multisite amyloid and tau quantification
Landau, Susan, Baker, Suzanne L. , Boswell, Martin S., Lee, JiaQie, Taggett, Jacinda , Ward, Tyler J. , Chadwick, Trevor, Murphy, Alice, DeCarli, Charles, Jack, Clifford R. , Jagust, William J. , Initiative, for the U.S. POINTER Study Group and for the Alzheimer's Disease Neuroimaging, DeCarli, Charles , DeCarli, Charles , Jack, Clifford R , Harrison, Theresa M. , Schwarz, Christopher G. , Vemuri, Prashanthi , Koeppe, Robert A. , Initiative, for the U.S. POINTER Study Group and for the Alzheimer's Disease Neuroimaging

Mayo Clinic

Alzheimer's & Dementia | November 19, 2024 | Volume: 21 | Issue: 1 | Pages: No page available

10.1002/alz.14378 | PMID 39559932 Get It

Abstract INTRODUCTION A key goal of the Alzheimer's Disease NeuroImaging Initiative (ADNI) positron emission tomography (PET) Core is to harmonize quantification of β‐amyloid (Aβ) and tau PET image data across multiple scanners and tracers. METHODS We developed an analysis pipeline (Berkeley PET Imaging Pipeline, B‐PIP) for ADNI Aβ and tau PET images and applied it to PET data from other multisite studies. Steps include image pre‐processing, refacing, magnetic resonance imaging (MRI)/PET co‐registration, visual quality control (QC), quantification of tracer uptake, and standardization of Aβ and tau standardized uptake value ratios (SUVrs) across tracers. RESULTS Measurements from 10,105 cross‐sectional and longitudinal Aβ and tau PET scans acquired in several studies between 2010 and 2024 can be processed, harmonized, and directly merged across tracers and cohorts. DISCUSSION The B‐PIP developed in ADNI is a scalable image harmonization approach used in several observational studies and clinical trials that facilitates rigorous Aβ and tau PET quantification and data sharing. Highlights Quantitative results from ADNI Aβ and tau PET data are generated using a rigorous, scalable image processing pipeline This pipeline has been applied to PET data from several other large, multisite studies and trials Quantitative outcomes are harmonizable across studies and are shared with the scientific community
Cerebrovascular markers of WMH and infarcts in ADNI: A historical perspective and future directions
Maillard, Pauline , Seiler, Stephan , DeCarli, Charles , Initiative, for the Alzheimer's Disease Neuroimaging, DeCarli, Charles , Maillard, Pauline , Fletcher, Evan M. , Carmichael, Owen , Schwarz, Christopher G. , Initiative, for the Alzheimer's Disease Neuroimaging

Mayo Clinic

Alzheimer's & Dementia | November 13, 2024 | Volume: 20 | Issue: 12 | Pages: 8953-8968

10.1002/alz.14358 | PMID 39535353 Get It

Abstract White matter hyperintensities (WMH) and infarcts found on magnetic resonance imaging (MR infarcts) are common biomarkers of cerebrovascular disease. In this review, we summarize the methods, publications, and conclusions stemming from the Alzheimer's Disease Neuroimaging Initiative (ADNI) related to these measures. We combine analysis of WMH and MR infarct data from across the three main ADNI cohorts with a review of existing literature discussing new methodologies and scientific findings derived from these data. Although ADNI inclusion criteria were designed to minimize vascular risk factors and disease, data across all the ADNI cohorts found consistent trends of increasing WMH volumes associated with advancing age, female sex, and cognitive impairment. ADNI, initially proposed as a study to investigate biomarkers of AD pathology, has also helped elucidate the impact of asymptomatic cerebrovascular brain injury on cognition within a cohort relatively free of vascular disease. Future ADNI work will emphasize additional vascular biomarkers. Highlights White matter hyperintensities (WMHs) are common to advancing age and likely reflect brain vascular injury among older individuals. WMH and to a lesser extent, magnetic resonance (MR) infarcts, affect risk for transition to cognitive impairment. WMHs and MR infarcts are present, even among Alzheimer's Disease Neuroimaging Initiative (ADNI) participants highly selected to have Alzheimer's disease (AD) as the primary pathology. WMH burden in ADNI is greater among individuals with cognitive impairment and has been associated with AD neurodegenerative markers and cerebral amyloidosis. The negative additive effects of cerebrovascular disease appear present, even in select populations, and future biomarker work needs to further explore this relationship.
Implementation and validation of face de‐identification (de‐facing) in ADNI4
Schwarz, Christopher G., Choe, Mark, Rossi, Stéphanie, Ittyerah, Ranjit, Fletcher, Evan, Maillard, Pauline , Singh, Baljeet , Harvey, Danielle , Malone, Ian B., Prosser, Lloyd , Matoush, Leonard, Ward, Chadwick P., Prakaashana, Carl M., Landau, Susan, Lee, JiaQie, DeCarli, Charles , Weiner, Michael W. , Jack, Clifford R. , Jagust, William, Tosun, Duygu , Initiative, for the Alzheimer's Disease Neuroimaging, DeCarli, Charles , Malone, Ian B. , Matoush, Leonard C, Jack, Clifford R , Harvey, Danielle J , Tosun, Duygu , Maillard, Pauline , Schwarz, Christopher G. , Rossi, Stephanie, Das, Sandhitsu R. , Senjem, Matthew L. , Koeppe, Robert A. , Yushkevich, Paul A. , Initiative, for the Alzheimer's Disease Neuroimaging

Mayo Clinic

Alzheimer's & Dementia | October 11, 2024 | Volume: 20 | Issue: 11 | Pages: 8048-8061

10.1002/alz.14303 | PMID 39392215 Get It

AbstractINTRODUCTIONRecent technological advances have increased the risk that de‐identified brain images could be re‐identified from face imagery. The Alzheimer's Disease Neuroimaging Initiative (ADNI) is a leading source of publicly available de‐identified brain imaging, who quickly acted to protect participants’ privacy.METHODSAn independent expert committee evaluated 11 face‐deidentification (“de‐facing”) methods and selected four for formal testing.RESULTSEffects of de‐facing on brain measurements were comparable across methods and sufficiently small to recommend de‐facing in ADNI. The committee ultimately recommended mri_reface for advantages in reliability, and for some practical considerations. ADNI leadership approved the committee's recommendation, beginning in ADNI4.DISCUSSIONADNI4 de‐faces all applicable brain images before subsequent pre‐processing, analyses, and public release. Trained analysts inspect de‐faced images to confirm complete face removal and complete non‐modification of brain. This paper details the history of the algorithm selection process and extensive validation, then describes the production workflows for de‐facing in ADNI.Highlights ADNI is implementing “de‐facing” of MRI and PET beginning in ADNI4. “De‐facing” alters face imagery in brain images to help protect privacy. Four algorithms were extensively compared for ADNI and mri_reface was chosen. Validation confirms mri_reface is robust and effective for ADNI sequences. Validation confirms mri_reface negligibly affects ADNI brain measurements.
Overview of ADNI MRI
Jack, Clifford R. , Arani, Arvin , Borowski, Bret, Crawford, Karen , DeCarli, Charles , Fletcher, Evan, Fox, Nick C. , Gunter, Jeffrey L. , Ittyerah, Ranjit, Harvey, Danielle , Jahanshad, Neda , Maillard, Pauline , Malone, Ian B., Reyes, Denise A., Thomas, David L. , Thompson, Paul M., Tosun, Duygu , Ward, Chadwick P., Weiner, Michael W., Initiative, Alzheimer's Disease Neuroimaging, DeCarli, Charles , Malone, Ian B. , Borowski, Bret J, Jack, Clifford R , Arani, Arvin , Fox, Nick C , Harvey, Danielle J , Tosun, Duygu , Maillard, Pauline , Cash, David M. , Das, Sandhitsu R. , Nir, Talia M. , Reid, Robert I. , Schwarz, Christopher G. , Senjem, Matthew L. , Thompson, Paul M. , Yushkevich, Paul A. , Initiative, Alzheimer's Disease Neuroimaging

Mayo Clinic

Alzheimer's & Dementia | September 11, 2024 | Volume: 20 | Issue: 10 | Pages: 7350-7360

10.1002/alz.14166 | PMID 39258539 Get It

Abstract The magnetic resonance imaging (MRI) Core has been operating since Alzheimer's Disease Neuroimaging Initiative's (ADNI) inception, providing 20 years of data including reliable, multi‐platform standardized protocols, carefully curated image data, and quantitative measures provided by expert investigators. The overarching purposes of the MRI Core include: (1) optimizing and standardizing MRI acquisition methods, which have been adopted by many multicenter studies and trials worldwide and (2) providing curated images and numeric summary values from relevant MRI sequences/contrasts to the scientific community. Over time, ADNI MRI has become increasingly complex. To remain technically current, the ADNI MRI protocol has changed substantially over the past two decades. The ADNI 4 protocol contains nine different imaging types (e.g., three dimensional [3D] T1‐weighted and fluid‐attenuated inversion recovery [FLAIR]). Our view is that the ADNI MRI data are a greatly underutilized resource. The purpose of this paper is to educate the scientific community on ADNI MRI methods and content to promote greater awareness, accessibility, and use. Highlights The MRI Core provides multi‐platform standardized protocols, carefully curated image data, and quantitative analysis by expert groups. The ADNI MRI protocol has undergone major changes over the past two decades to remain technically current. As of April 25, 2024, the following numbers of image series are available: 17,141 3D T1w; 6877 FLAIR; 3140 T2/PD; 6623 GRE; 3237 dMRI; 2846 ASL; 2968 TF‐fMRI; and 2861 HighResHippo (see Table 1 for abbreviations). As of April 25, 2024, the following numbers of quantitative analyses are available: FreeSurfer 10,997; BSI 6120; tensor based morphometry (TBM) and TBM‐SYN 12,019; WMH 9944; dMRI 1913; ASL 925; TF‐fMRI NFQ 2992; and medial temporal subregion volumes 2726 (see Table 4 for abbreviations). ADNI MRI is an underutilized resource that could be more useful to the research community.
The ADNI4 Digital Study: A novel approach to recruitment, screening, and assessment of participants for AD clinical research
Miller, Melanie J. , Diaz, Adam , Conti, Catherine , Albala, Bruce, Flenniken, Derek , Fockler, Juliet , Kwang, Winnie, Sacrey, Diana Truran, Ashford, Miriam T. , Skirrow, Caroline , Weston, Jack , Fristed, Emil , Farias, Sarah Tomaszewski , Korecka, Magda, Wan, Yang , Aisen, Paul, Harvey, Danielle, Petersen, Ronald C. , Okonkwo, Ozioma C. , Weiner, Michael W., Nosheny, Rachel L. , Initiative, Alzheimer's Disease Neuroimaging, Harvey, Danielle , Harvey, Danielle J , Beckett, Laurel , Harvey, Danielle, Lee, Edward B. , Li, Yi‐Ju , Mindt, Mónica Rivera , Initiative, Alzheimer's Disease Neuroimaging

Mayo Clinic

Alzheimer's & Dementia | September 2, 2024 | Volume: 20 | Issue: 10 | Pages: 7232-7247

10.1002/alz.14234 | PMID 39219153 Get It

AbstractINTRODUCTIONWe evaluated preliminary feasibility of a digital, culturally‐informed approach to recruit and screen participants for the Alzheimer's Disease Neuroimaging Initiative (ADNI4).METHODSParticipants were recruited using digital advertising and completed digital surveys (e.g., demographics, medical exclusion criteria, 12‐item Everyday Cognition Scale [ECog‐12]), Novoic Storyteller speech‐based cognitive test). Completion rates and assessment performance were compared between underrepresented populations (URPs: individuals from ethnoculturally minoritized or low education backgrounds) and non‐URPs.RESULTSOf 3099 participants who provided contact information, 654 enrolled in the cohort, and 595 completed at least one assessment. Two hundred forty‐seven participants were from URPs. Of those enrolled, 465 met ADNI4 inclusion criteria and 237 evidenced possible cognitive impairment from ECog‐12 or Storyteller performance. URPs had lower ECog and Storyteller completion rates. Scores varied by ethnocultural group and educational level.DISCUSSIONPreliminary results demonstrate digital recruitment and screening assessment of an older diverse cohort, including those with possible cognitive impairment, are feasible. Improving engagement and achieving educational diversity are key challenges.Highlights A total of 654 participants enrolled in a digital cohort to facilitate ADNI4 recruitment. Culturally‐informed digital ads aided enrollment of underrepresented populations. From those enrolled, 42% were from underrepresented ethnocultural and educational groups. Digital screening tools indicate > 50% of participants likely cognitively impaired. Completion rates and assessment performance vary by ethnocultural group and education.
A Protocol for the Inclusion of Minoritized Persons in Alzheimer Disease Research From the ADNI3 Diversity Taskforce
Okonkwo, Ozioma C. , Ashford, Miriam T. , Conti, Catherine , Strong, Joe, Raman, Rema , Nosheny, Rachel L. , Flenniken, Derek , Miller, Melanie J. , Diaz, Adam , Soto, Annabelle M., Ances, Beau M. , Beigi, Maryam , Doraiswamy, P. Murali , Duara, Ranjan , Farlow, Martin R. , Grossman, Hillel, Mintzer, Jacobo , Reist, Christopher , Rogalskı, Emily , Sabbagh, Marwan N. , Salloway, Stephen, Schneider, Lon S. , Petersen, Ronald C. , Aisen, Paul , Weiner, Michael W., Initiative, Alzheimer’s Disease Neuroimaging, Ances, Beau M , Mindt, Mónica Rivera , Donohue, Michael , Duara, Ranjan , Shah, Raj C. , Initiative, Alzheimer’s Disease Neuroimaging

Mayo Clinic

JAMA Network Open | August 9, 2024 | Volume: 7 | Issue: 8 | Pages: e2427073

10.1001/jamanetworkopen.2024.27073 | PMID 39120898 Get It

ImportanceBlack or African American (hereinafter, Black) and Hispanic or Latino/a/x (hereinafter, Latinx) adults are disproportionally affected by Alzheimer disease, but most research studies do not enroll adequate numbers of both of these populations. The Alzheimer’s Disease Neuroimaging Initiative-3 (ADNI3) launched a diversity taskforce to pilot a multipronged effort to increase the study inclusion of Black and Latinx older adults.ObjectiveTo describe and evaluate the culturally informed and community-engaged inclusion efforts to increase the screening and enrollment of Black and Latinx older adults in ADNI3.Design, Setting, and ParticipantsThis cross-sectional study used baseline data from a longitudinal, multisite, observational study conducted from January 15, 2021, to July 12, 2022, with no follow-up. The study was conducted at 13 ADNI3 sites in the US. Participants included individuals aged 55 to 90 years without cognitive impairment and those with mild cognitive impairment or Alzheimer disease.ExposuresEfforts included (1) launch of an external advisory board, (2) changes to the study protocol, (3) updates to the digital prescreener, (4) selection and deployment of 13 community-engaged research study sites, (5) development and deployment of local and centralized outreach efforts, and (6) development of a community-science partnership board.Main Outcomes and MeasuresScreening and enrollment numbers from centralized and local outreach efforts, digital advertisement metrics, and digital prescreener completion.ResultsA total of 91 participants enrolled in the trial via centralized and local outreach efforts, of which 22 (24.2%) identified as Latinx and 55 (60.4%) identified as Black (median [IQR] age, 65.6 [IQR, 61.5-72.5] years; 62 women [68.1%]). This represented a 267.6% increase in the monthly rate of enrollment (before: 1.11 per month; during: 4.08 per month) of underrepresented populations. For the centralized effort, social media advertisements were run between June 1, 2021, and July 31, 2022, which resulted in 2079 completed digital prescreeners, of which 1289 met criteria for subsequent site-level screening. Local efforts were run between June 1, 2021, to July 31, 2022. A total of 151 participants underwent site-level screening (100 from local efforts, 41 from centralized efforts, 10 from other sources).Conclusions and RelevanceIn this cross-sectional study of pilot inclusion efforts, a culturally informed, community-engaged approach increased the inclusion of Black and Latinx participants in an Alzheimer disease cohort study.
Use of ultrasound gel to mitigate risks of skin burns from non-actively cooled mic rowave applicators
Ren, Liqiang , Woodrum, David A. , Gorny, Krzysztof R. , Felmlee, Joel P. , Thompson, Scott M. , Xi, Yin, Lu, Aiming , Adamo, Daniel A.

Mayo Clinic

American Journal of Interventional Radiology | May 9, 2024 | Volume: 8 | Issue: No issue available | Pages: 5

10.25259/ajir_3_2024 Get It

The purpose of this study is to investigate the potential of using ultrasound gel to mitigate the risks of skin burn at the insertion site during microwave ablation (MWA) using non-actively cooled applicators. Ex vivo experiments in porcine tissue were conducted using two identical MWA systems. Five MWA scenarios were tested at different applicator insertion depths with an ultrasound gel layer applied at the applicator insertion sites: 8 cm insertion depth with and without 4 cm thick gel, 10 cm insertion depth with and without 2 cm thick gel, and 12 cm insertion depth without gel (reference). In all experiments, temperature elevations at the applicator insertion site on the tissue surface were recorded using thermal sensors in all experiments during 10-min MWA. The application of ultrasound gel and increasing applicator insertion depths resulted in measurable reductions in temperature elevations at the applicator insertion sites. For an insertion depth of 8 cm, the temperature elevations were 39.9 ± 4.7°C and 23.2±6.5°C without and with gel, respectively (P < 0.001). For an insertion depth of 10 cm, the temperature elevations were 20.8 ± 1.5°C and 14.4 ± 1.5°C without and with gel, respectively (P < 0.001). The maximal temperature elevations corresponding to an 8 cm insertion depth with gel were comparable with those corresponding to a 10 cm insertion depth without gel. Similarly, the maximal temperature elevations (12.2 ± 1.8°C) corresponding to 12 cm insertion depth without gel were comparable to those corresponding to 10 cm insertion depth with gel. Applying ultrasound gel at the applicator insertion site can significantly reduce temperature elevations at the tissue surface during MWA procedures.